IMMUTEP ADR |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.265 USD | +12.69% |
|
+17.01% | -5.42% |
| 08:47am | Rising US Rate Cut Bets Lift Australian Shares to Record High | MT |
| 06:53am | Immutep Surges 19% Following Positive Results in Head, Neck Cancer Trial | MT |
| Sales 2024 * | 3.11M 2.1M | Sales 2025 * | 4.57M 3.09M | Capitalization | 420M 284M |
|---|---|---|---|---|---|
| Net income 2024 * | -46M -31.1M | Net income 2025 * | -56M -37.86M | EV / Sales 2024 * | 85.7 x |
| Net cash position 2024 * | 154M 104M | Net cash position 2025 * | 105M 70.72M | EV / Sales 2025 * | 69 x |
| P/E ratio 2024 * |
-7.96
x | P/E ratio 2025 * |
-7.02
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.92% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.50% | ||
| 1 week | +1.52% | ||
| 1 month | -25.83% | ||
| 3 months | -20.55% | ||
| 6 months | -21.48% | ||
| Current year | -16.25% |
1 week
1.91
2.06
1 month
1.662.80
Current year
1.663.34
1 year
1.583.34
3 years
1.475.00
5 years
0.537.95
10 years
0.5321.60
| Managers | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
David Fang
DFI | Director of Finance/CFO | - | 18-02-28 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 13-05-07 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
Anne Anderson
BRD | Director/Board Member | - | Feb. 13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-12 | 2.28 | +13.43% | 5 149 625 |
| 24-07-11 | 2.01 | +0.50% | 1,004,229 |
| 24-07-10 | 2 | +1.01% | 133,731 |
| 24-07-09 | 1.98 | +1.02% | 82,119 |
| 24-07-08 | 1.96 | +1.03% | 132,481 |
Delayed Quote Nasdaq, July 11, 2024 at 04:00 pm EDT
More quotes
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3âs ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Calendar
07:00pm
- ESMO Virtual Plenary Session
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.295
AUD
Average target price
0.942
AUD
Spread / Average Target
+219.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.50% | 47.07B | |
| +47.19% | 42.06B | |
| -5.16% | 39.98B | |
| +36.37% | 33.02B | |
| -7.79% | 27.9B | |
| +18.06% | 27.63B | |
| +47.29% | 14.37B | |
| +41.91% | 13.45B | |
| -1.02% | 12.03B |
- Stock Market
- Equities
- IMM Stock
- IMMP Stock
